Company Overview - Zhenbaojiao (SH 603567) announced on December 19 that its controlling shareholder, Chuangda Group, has pledged 48.6 million shares to Longjiang Bank for a one-year term [1] - As of the announcement date, Chuangda Group has pledged a total of approximately 437 million shares, representing 80.9% of its holdings [1] Financial Performance - For the year 2024, Zhenbaojiao's revenue composition is as follows: pharmaceutical manufacturing accounts for 87.78%, pharmaceutical commerce for 11.13%, and other businesses for 1.09% [1] - The current market capitalization of Zhenbaojiao is 9.3 billion yuan [1]

截至2025年12月18日,创达集团累计质押公司股票数量为437,382,039 股，占其持有公司股份总数的 80.90%，占公司总股本的 46.48%。 控股股东累计质押股份数量（含本次）占其持股数量比例超过 80%，敬 请广大投资者注意投资风险。 公司于近日收到控股股东创达集团《关于对黑龙江珍宝岛药业股份有限公司 股票质押及解质押的函》的通知，具体情况如下： 一、股份质押情况 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-086 黑龙江珍宝岛药业股份有限公司 关于控股股东部分股份质押及解质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"）控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）因可交换公司债券换股， 截至 2025 年 12 月 18 日持有公司股份 54,066.7339 万股无限售流通股，占公司 总股本的 57.46%。创达集团未间接持有公司股份，无一致行动人。 近日，创达集团将持有的公司 4,860 ...

Core Viewpoint - The company held its third extraordinary general meeting of shareholders for 2025, where no resolutions were rejected, and key decisions were made regarding the appointment of auditors and adjustments to the convertible bond exchange price [2][4][6]. Group 1: Meeting Details - The extraordinary general meeting was held on December 11, 2025, in Harbin, China [2]. - The meeting was convened by the board of directors and chaired by Chairman Fang Tonghua, utilizing a combination of on-site and online voting methods [2][3]. - All six current directors and the board secretary attended the meeting [3]. Group 2: Resolutions and Voting - A resolution to reappoint the auditing firm for the 2025 fiscal year was passed [4]. - There were no significant matters requiring a vote from shareholders holding less than 5% of shares [4]. Group 3: Legal Oversight - The meeting was witnessed by Beijing Lantai Law Firm, with lawyers Zhang Buyong and Cao Wenwen providing legal opinions confirming the legality of the meeting's procedures and outcomes [5]. Group 4: Convertible Bond Adjustment - The controlling shareholder, Heilongjiang Chuangda Group, announced an adjustment to the exchange price of its non-publicly issued convertible bonds due to a decline in the stock price [6]. - The exchange price will be reduced from 10.54 CNY per share to 9.49 CNY per share, effective December 18, 2025, following a period where the stock price was below the original exchange price for 15 consecutive trading days [6].

黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-085 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第二期）（以下简称"本期可交 债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 6 月 28 日完成本期可交债的发行。本期 可交债简称"23 创 02EB"，债券代码为"137177"，发行规模 0.9 亿元，债券期 限 3 年。具体内容详见公司于 2023 年 6 月 30 日在上海证券交易所网站披露的临 2023-059 号公告。 二、控股股东可交换公司债券本次换股价格调整情况 根据《黑龙江创达集团有限公司 2023 年面向专业投资者非公开发行可交换 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临2025-084 黑龙江珍宝岛药业股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 12 月 11 日 (二)股东会召开的地点：哈尔滨市平房开发区烟台一路 8 号 | 1、出席会议的股东和代理人人数 | 173 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 494,478,947 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 52.5561 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，公司董事长方同华先生主持。本次会议以现场 和网络投票相结合的方式对股东会通知中列明的事项进行了投票表决，表决方式 符 ...

北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2025 年第三次临时股东会的 法 律 意 见 书 兰台意字（2025）第【7937】号 地址：北京市朝阳区曙光西里甲 1 号第三置业大厦 B 座 29 层 电话：（8610）52287799 传真：（8610）58220039 网址：www.lantai.cn 法律意见书 北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2025 年第三次临时股东会的 法 律 意 见 书 兰台意字（2025）第【7937】号 致：黑龙江珍宝岛药业股份有限公司 北京市兰台律师事务所（以下简称"本所"）接受黑龙江珍宝岛药业股份有 限公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 12 月 11 日召开的 2025 年第三次临时股东会（以下简称"本次股东会"或"会议"）。 现依据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司股东 会规则》（以下简称"《股东会规则》"）等法律、行政法规、规范性文件及《黑 龙江珍宝岛药业股份有限公司章程》（以下简称"《公司章程》"）的规定，本 所律师就本次股东会的相关事项进行见证并出具本法律意见书。 对 ...

Core Viewpoint - The major shareholders of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. have completed their share reduction plan, resulting in both shareholders no longer holding more than 5% of the company's shares [3][5]. Group 1: Shareholder Information - Before the reduction plan, Baoding Junze Fanglong Equity Investment Center (Limited Partnership) held 55,792,905 shares, accounting for 5.93% of the total share capital, while Huzhou Saihan Equity Investment Partnership (Limited Partnership) held 47,098,180 shares, accounting for 5.01% [2]. Group 2: Reduction Plan Implementation - The reduction plan allowed Baoding Junze Fanglong to reduce up to 28,229,895 shares, which is not more than 3% of the total share capital, with a maximum of 9,409,965 shares through centralized bidding and 18,819,930 shares through block trading [4]. - Huzhou Saihan was permitted to reduce up to 9,409,965 shares through centralized bidding, which is also not more than 1% of the total share capital [4]. Group 3: Actual Reduction Results - Baoding Junze Fanglong reduced 9,028,305 shares through centralized bidding (0.96% of total share capital) and 6,924,700 shares through block trading (0.74% of total share capital) [5]. - Huzhou Saihan reduced 1,011,654 shares through centralized bidding (0.11% of total share capital) [5].

Group 1 - The company, Zhenbaodao, announced a reduction in shareholding by two entities, Bozhou Junzefanglong and Huzhou Saihan, with a total of 16,964,655 shares reduced, representing 1.70% of the company's total share capital [1] - The revenue composition for Zhenbaodao in 2024 is as follows: pharmaceutical industry accounts for 87.78%, pharmaceutical commerce for 11.13%, and other businesses for 1.09% [1] - As of the report date, Zhenbaodao's market capitalization is 9.6 billion yuan [1]

Core Viewpoint - The company, Zhenbao Island (603567.SH), has completed a share reduction plan involving two entities, resulting in a significant decrease in its total shareholding [1] Group 1: Share Reduction Details - Bozhou Junze Fanglong reduced its holdings by a total of 15.95 million shares, which is 0.96% through centralized bidding and 0.74% through block trading, making a combined total of 1.59 million shares [1] - Huzhou Saihan reduced its holdings by 1.01 million shares, accounting for 0.11% of the company's total share capital [1]

证券代码：603567 证券简称：珍宝岛 公告编号：临2025-083 黑龙江珍宝岛药业股份有限公司 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，亳州郡泽方隆股权投资中心（有限合伙）（以下简称 "亳州郡泽方隆"）持有黑龙江珍宝岛药业股份有限公司（以下简称"公司"）股 份 55,792,905 股，占公司总股本的 5.93%；湖州赛瀚股权投资合伙企业（有限 合伙）（以下简称"湖州赛瀚"）持有公司股份 47,098,180 股，占公司总股本的 5.01%。 本次减持计划结束后，亳州郡泽方隆和湖州赛瀚不再是公司持股 5%以上 的股东。 减持计划的实施结果情况 2025 年 8 月 20 日，公司披露了《黑龙江珍宝岛药业股份有限公司 5%以上股 东减持股份计划公告》（公告编号：临 2025-064）。亳州郡泽方隆自减持计划公 告之日起 15 个交易日后的 3 个月内，通过集中竞价交易或大宗交易方式合计减 持不超过 28,229,895 ...